A Phase 2 interventional study of danicamtiv in Primary Familial Dilated Cardiomyopathy, sponsored by Bristol-Myers Squibb. Terminated at 19 sites in 4 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-05-21.
Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies in Cardiomyopathy, Dilated with a site in United States — 14 open to participants now, 20 under way, 2 of them phase 3. Cardiomyopathy, Dilated · United States.
Among the 64 studies in Cardiomyopathy, Dilated with a site in United States, this one is the 19th largest by enrollment of the 42 interventional ones that give a count, is one of 4 that started in 2020, is one of 8 in phase 2, and was the 48th registered.
255 studies on the registry are indexed under Cardiomyopathy, Dilated; 66 are open to participants now.
Browse Cardiomyopathy, Dilated studies →14 of the 64 studies in Cardiomyopathy, Dilated with a site in United States are open now. Recruiting first, the newest first:
Affinia Therapeutics · Sites in United States, Canada
Ages 18–70
Kardigan, Inc. · Sites in United States, Belgium, Denmark and 8 more countries
Ages 18+
Nuevocor Pte. Ltd. · Sites in United States
Ages 18+
Rocket Pharmaceuticals Inc. · Sites in United States
Ages 18–65
Kardigan, Inc. · Sites in United States, Belgium, Denmark and 8 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 53 Cardiomyopathy, Dilated studies recruiting now, 30 (57%) set no upper age limit and 15 (28%) stop at 75 or younger; 13 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 17 · Phase 3 5 · Phase 4 2
First in 1992; this study’s year is marked. 4 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 41 is close to the median of 43 across 145 interventional studies indexed under Cardiomyopathy, Dilated.
Median enrollment 37 across the 42 interventional studies, 166 across the 20 observational. Of the 38 that completed or were terminated, 16 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 64 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Bristol-Myers Squibb has 3 studies filed under Cardiomyopathy, Dilated — fewer than ten, so there is no comparison to draw.
7 of the studies in Cardiomyopathy, Dilated with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07210723Phase 3Kardigan, Inc.A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy | 2027-09 |
| NCT04638621Ohio State UniversityDilated Cardiomyopathy-Cardiac Magnetic Resonance (DCM-CMR) Ancillary Study | 2026-12 |
| NCT06688396Lancaster General HospitalDilated Cardiomyopathy Detection Using AI and Screening With Mobile Technology (DCM-DETECT) | 2026-12 |
| NCT04476901Joshua M HareAdministration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy | 2027-04 |
| NCT06464588Emory UniversityA Phase 1 Open-Label Study of the Safety of Intravenous Allogeneic Neonatal Mesenchymal Cells (nMSCs) in Young Adult (1A) and Pediatric (1B) Patients With Dilated Cardiomyopathy (DCM) | 2027-07 |
Add all 7 to your calendar (.ics) → With an account.
Among the 64 studies in Cardiomyopathy, Dilated with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this Phase 2a study is to establish safety and preliminary efficacy of treatment with danicamtiv in patients with primary dilated cardiomyopathy (DCM) due to MYH7 or TTN variants or other causalities.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Primary DCM due to MYH7 or TTN Variant or due to other causalities not related to MYH7 or TTN variants
Drug: danicamtiv
Myosin activator
Also known as: MYK-491, BMS-986434
Number of Participants With Adverse Events (AEs) in Part A
An AE is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment.
Time frame: From first dose to 30 days post last dose (Up to approximately 15 weeks)
Number of Participants With Serious Adverse Events (SAEs) in Part A
An SAE is defined as any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability or permanent damage, is a congenital anomaly/birth defect, is an important medical event.
Time frame: From first dose to 30 days post last dose (Up to approximately 15 weeks)
Number of Participants With Safety Laboratory Assessments by Intensity in Part A
Number of participants with safety laboratory assessments by intensity. Mild=An event that is easily tolerated by the participant, causing minimal discomfort and not interfering with everyday activities; Moderate= An event causing sufficient discomfort and interferes with normal everyday activities.
Time frame: From first dose to 14 days post last dose (Up to approximately 13 weeks)
Number of Participants With Clinically Significant Changes in Physical Examinations in Part A
Number of participants with clinically significant changes in physical examinations.
Time frame: From first dose to 30 days post last dose (Up to approximately 15 weeks)
Number of Participants With Clinically Significant Changes in Vital Signs in Part A
Number of participants with clinically significant changes in vital signs.
Time frame: From first dose to 30 days post last dose (Up to approximately 15 weeks)
Number of Participants With Clinically Significant Changes in 12-Lead ECG Recordings in Part A
Number of participants with clinically significant changes in 12-lead ECG recordings.
Time frame: From first dose to 30 days post last dose (Up to approximately 15 weeks)
Number of Participants With Treatment Emergent Adverse Events (TEAEs) by Intensity in Part A
An AE is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment. Mild=An event that is easily tolerated by the participant, causing minimal discomfort and not interfering with everyday activities; Moderate= An event causing sufficient discomfort and interferes with normal everyday activities. Severe= An event preventing normal everyday activities. (An AE that is assessed as severe should not be confused with a SAE. Severe is a category utilized for rating the intensity of an event; and both AEs and SAEs can be assessed as severe.)
Time frame: From first dose to 14 days post last dose (Up to approximately 13 weeks)
Transthoracic Echo (TTE) Left Ventricular Ejection Time (LVET) Change From Baseline
Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.
Time frame: Part A: Baseline, end of treatment period 1. end of treatment period 2, early termination; Part B: Baseline, weeks 2, 6, 12, 24, 36, 48, and early termination
Transthoracic Echo (TTE) Left Ventricular Stroke Volume (LVSV) Change From Baseline
Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.
Time frame: Part A: Baseline, end of treatment period 1. end of treatment period 2, early termination; Part B: Baseline, weeks 2, 6, 12, 24, 36, 48, and early termination
Transthoracic Echo (TTE) Left Ventricular Ejection Fraction (LVEF) Change From Baseline
Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.
Time frame: Part A: Baseline, end of treatment period 1. end of treatment period 2, early termination; Part B: Baseline, weeks 2, 6, 12, 24, 36, 42, 48, and early termination
Transthoracic Echo (TTE) Left Ventricular Global Longitudinal Strain (LVGLS) Change From Baseline
Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.
Time frame: Part A: Baseline, end of treatment period 1. end of treatment period 2, early termination; Part B: Baseline, weeks 2, 6, 12, 24, 36, 42, 48, and early termination
Transthoracic Echo (TTE) Left Ventricular Global Circumferential Strain (LVGCS) Change From Baseline
Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.
Time frame: Part A: Baseline, end of treatment period 1. end of treatment period 2, early termination; Part B: Baseline, weeks 2, 6, 12, 24, 36, 42, 48, and early termination
Transthoracic Echo (TTE) Tissue Doppler Imaging (TDI) S Prime Lateral Change From Baseline
Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.
Time frame: Part A: Baseline, end of treatment period 1. end of treatment period 2, early termination; Part B: Baseline, weeks 2, 6, 12, 24, 36, 48, and early termination
Transthoracic Echo (TTE) Tissue Doppler Imaging (TDI) S Prime Septal Change From Baseline
Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.
Time frame: Part A: Baseline, end of treatment period 1. end of treatment period 2, early termination; Part B: Baseline, weeks 2, 6, 12, 24, 36, 48, and early termination
Transthoracic Echo (TTE) Tissue Doppler Imaging (TDI) Left Ventricular End-Systolic Diameter (LVESD) Change From Baseline
Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.
Time frame: Part A: Baseline, end of treatment period 1. end of treatment period 2, early termination; Part B: Baseline, weeks 2, 6, 12, 24, 36, 48, and early termination
Transthoracic Echo (TTE) Tissue Doppler Imaging (TDI) Left Ventricular End-Systolic Volumen Index (LVESVi) Change From Baseline
Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.
Time frame: Part A: Baseline, end of treatment period 1. end of treatment period 2, early termination; Part B: Baseline, weeks 2, 6, 12, 24, 36, 42, 48, and early termination
Transthoracic Echo (TTE) Tissue Doppler Imaging (TDI) Left Ventricular End-Diastolic Diameter (LVEDD) Change From Baseline
Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.
Time frame: Part A: Baseline, end of treatment period 1. end of treatment period 2, early termination; Part B: Baseline, weeks 2, 6, 12, 24, 36, 48, and early termination
Transthoracic Echo (TTE) Tissue Doppler Imaging (TDI) Left Ventricular End-Diastolic Volumen Index (LVEDVi) Change From Baseline
Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.
Time frame: Part A: Baseline, end of treatment period 1. end of treatment period 2, early termination; Part B: Baseline, weeks 2, 6, 12, 24, 36, 42, 48, and early termination
Transthoracic Echo (TTE) Tissue Doppler Imaging (TDI) E Prime Lateral Change From Baseline
Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.
Time frame: Part A: Baseline, end of treatment period 1. end of treatment period 2, early termination; Part B: Baseline, weeks 2, 6, 12, 24, 36, 48, and early termination
Transthoracic Echo (TTE) Tissue Doppler Imaging (TDI) E Prime Septal Change From Baseline
Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.
Time frame: Part A: Baseline, end of treatment period 1. end of treatment period 2, early termination; Part B: Baseline, weeks 2, 6, 12, 24, 36, 48, and early termination
Transthoracic Echo (TTE) E/E Prime Average Ratio Change From Baseline
Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.
Time frame: Part A: Baseline, end of treatment period 1. end of treatment period 2, early termination; Part B: Baseline, weeks 2, 6, 12, 24, 36, 48, and early termination
Transthoracic Echo (TTE) E/E Prime Lateral Ratio Change From Baseline
Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.
Time frame: Part A: Baseline, end of treatment period 1. end of treatment period 2, early termination; Part B: Baseline, weeks 2, 6, 12, 24, 36, 48, and early termination
Transthoracic Echo (TTE) E/E Prime Septal Ratio Change From Baseline
Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.
Time frame: Part A: Baseline, end of treatment period 1. end of treatment period 2, early termination; Part B: Baseline, weeks 2, 6, 12, 24, 36, 48, and early termination
Transthoracic Echo (TTE) Ratio of Peak Inflow Velocities in Early and Late Diastole - E/A Change From Baseline
Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.
Time frame: Part A: Baseline, end of treatment period 1. end of treatment period 2, early termination; Part B: Baseline, weeks 2, 6, 12, 24, 36, 48, and early termination
Transthoracic Echo (TTE) Left Atrial Minimum Volume (LAminV) Change From Baseline
Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.
Time frame: Part A: Baseline, end of treatment period 1. end of treatment period 2, early termination; Part B: Baseline, weeks 2, 6, 12, 24, 36, 48, and early termination
Transthoracic Echo (TTE) Left Atrial Maximum Volume Index (LAmaxVi) Change From Baseline
Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.
Time frame: Part A: Baseline, end of treatment period 1. end of treatment period 2, early termination; Part B: Baseline, weeks 2, 6, 12, 24, 36, 48, and early termination
Transthoracic Echo (TTE) Left Atrial Emptying Fraction (LAEF) Change From Baseline
Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.
Time frame: Part A: Baseline, end of treatment period 1. end of treatment period 2, early termination; Part B: Baseline, weeks 2, 6, 12, 24, 36, 48, and early termination
Transthoracic Echo (TTE) Left Atrial Function Index (LAFI) Change From Baseline
Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days. Higher LAFI values are considered better left atrial function while lower LFAI values may indicate left atrial dysfunction.
Time frame: Part A: Baseline, end of treatment period 1. end of treatment period 2, early termination; Part B: Baseline, weeks 2, 6, 12, 24, 36, 48, and early termination
| Milestone | Part A - MYH7 - MYK-491 | Part A - TTN - MYK-491 | Part A - DCM-Genetic - MYK-491 | Part A - DCM-Non Genetic - MYK-491 | Part B - MYH7 - MYK-491 | Part B - TTN - MYK-491 | Part B - DCM-Non Genetic - MYK-491 |
|---|---|---|---|---|---|---|---|
| Started | 12 | 14 | 5 | 10 | 0 | 0 | 0 |
| Started part b | 8 | 7 | 0 | 4 | 0 | 0 | 0 |
| Completed | 11 | 14 | 5 | 10 | 0 | 0 | 0 |
| Not completed | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part A - MYH7 - MYK-491 | Part A - TTN - MYK-491 | Part A - DCM-Genetic - MYK-491 | Part A - DCM-Non Genetic - MYK-491 | Part B - MYH7 - MYK-491 | Part B - TTN - MYK-491 | Part B - DCM-Non Genetic - MYK-491 |
|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 8 | 7 | 4 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 8 | 7 | 4 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 0 | 0 | 7 | 5 | 3 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
An AE is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment.
| Participants | Part A - MYH7 - MYK-491 | Part A - TTN - MYK-491 | Part A - DCM-Genetic - MYK-491 | Part A - DCM-Non Genetic - MYK-491 |
|---|---|---|---|---|
| Number of Participants With Adverse Events (AEs) in Part A | 9 | 9 | 4 | 4 |
An SAE is defined as any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability or permanent damage, is a congenital anomaly/birth defect, is an important medical event.
| Participants | Part A - MYH7 - MYK-491 | Part A - TTN - MYK-491 | Part A - DCM-Genetic - MYK-491 | Part A - DCM-Non Genetic - MYK-491 |
|---|---|---|---|---|
| Number of Participants With Serious Adverse Events (SAEs) in Part A | 0 | 0 | 0 | 0 |
Number of participants with safety laboratory assessments by intensity. Mild=An event that is easily tolerated by the participant, causing minimal discomfort and not interfering with everyday activities; Moderate= An event causing sufficient discomfort and interferes with normal everyday activities.
| Participants | Part A - MYH7 - MYK-491 | Part A - TTN - MYK-491 | Part A - DCM-Genetic - MYK-491 | Part A - DCM-Non Genetic - MYK-491 |
|---|---|---|---|---|
| Alanine aminotransferase increased Mild | 1 | 0 | 1 | 0 |
| Aspartate aminotransferase increased Mild | 1 | 0 | 1 | 0 |
| Blood creatinine increased Moderate | 0 | 0 | 1 | 0 |
| Fibrin D dimer increased Moderate | 0 | 1 | 0 | 0 |
| Hyperkalaemia Mild | 0 | 1 | 0 | 0 |
| Hyperkalaemia Moderate | 0 | 0 | 1 | 0 |
Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.
| msec | Part A - MYH7 - MYK-491 | Part A - TTN - MYK-491 | Part A - DCM-Genetic - MYK-491 | Part A - DCM-Non Genetic - MYK-491 | Part B - MYH7 - MYK-491 | Part B - TTN - MYK-491 | Part B - DCM-Non Genetic - MYK-491 |
|---|---|---|---|---|---|---|---|
| End of treatment period 1 | 12.1 ± 23.7 | 7.4 ± 28.8 | -3.5 ± 8.7 | 3.3 ± 36.3 | — | — | — |
| End of treatment period 2 | 29.4 ± 31.0 | 29.0 ± 25.4 | -5.6 ± 18.2 | 15.2 ± 54.4 | — | — | — |
| week 2 | — | — | — | — | 38.3 ± 30.0 | 44.3 ± 16.3 | 20.3 ± 34.5 |
| week 6 | — | — | — | — | 25.3 ± 22.3 | 53.3 ± 43.6 | 20.5 ± 67.2 |
| week 12 | — | — | — | — | 32.1 ± 27.4 | 38.2 ± 33.5 | 44.0 ± NA |
| week 24 | — | — | — | — | 39.8 ± 46.3 | 59.8 ± 39.5 | — |
| week 36 | — | — | — | — | — | 47.5 ± 9.2 | — |
| week 48 | — | — | — | — | 42.3 ± 40.3 | 30.3 ± 34.0 | — |
| Early termination | -23.0 ± NA | — | — | — | 13.5 ± 44.4 | -1.4 ± 20.5 | -14.3 ± 35.2 |
Number of participants with clinically significant changes in physical examinations.
| Participants | Part A - MYH7 - MYK-491 | Part A - TTN - MYK-491 | Part A - DCM-Genetic - MYK-491 | Part A - DCM-Non Genetic - MYK-491 |
|---|---|---|---|---|
| Number of Participants With Clinically Significant Changes in Physical Examinations in Part A | 0 | 1 | 0 | 0 |
Number of participants with clinically significant changes in vital signs.
| Participants | Part A - MYH7 - MYK-491 | Part A - TTN - MYK-491 | Part A - DCM-Genetic - MYK-491 | Part A - DCM-Non Genetic - MYK-491 |
|---|---|---|---|---|
| Number of Participants With Clinically Significant Changes in Vital Signs in Part A | 0 | 0 | 0 | 0 |
Number of participants with clinically significant changes in 12-lead ECG recordings.
| Participants | Part A - MYH7 - MYK-491 | Part A - TTN - MYK-491 | Part A - DCM-Genetic - MYK-491 | Part A - DCM-Non Genetic - MYK-491 |
|---|---|---|---|---|
| Number of Participants With Clinically Significant Changes in 12-Lead ECG Recordings in Part A | 0 | 0 | 0 | 0 |
An AE is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment. Mild=An event that is easily tolerated by the participant, causing minimal discomfort and not interfering with everyday activities; Moderate= An event causing sufficient discomfort and interferes with normal everyday activities. Severe= An event preventing normal everyday activities. (An AE that is assessed as severe should not be confused with a SAE. Severe is a category utilized for rating the intensity of an event; and both AEs and SAEs can be assessed as severe.)
| Participants | Part A - MYH7 - MYK-491 | Part A - TTN - MYK-491 | Part A - DCM-Genetic - MYK-491 | Part A - DCM-Non Genetic - MYK-491 |
|---|---|---|---|---|
| Mild | 8 | 6 | 3 | 4 |
| Moderate | 0 | 1 | 1 | 0 |
| Severe | 0 | 0 | 0 | 0 |
Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.
| mL | Part A - MYH7 - MYK-491 | Part A - TTN - MYK-491 | Part A - DCM-Genetic - MYK-491 | Part A - DCM-Non Genetic - MYK-491 | Part B - MYH7 - MYK-491 | Part B - TTN - MYK-491 | Part B - DCM-Non Genetic - MYK-491 |
|---|---|---|---|---|---|---|---|
| End of treatment period 1 | 10.581 ± 9.814 | 5.628 ± 3.127 | 1.855 ± 7.979 | -5.897 ± 17.237 | — | — | — |
| End of treatment period 2 | 10.151 ± 19.585 | 1.243 ± 14.275 | 1.050 ± 13.379 | 2.172 ± 20.000 | — | — | — |
| week 2 | — | — | — | — | 15.576 ± 11.932 | -7.600 ± 14.358 | -15.678 ± 18.882 |
| week 6 | — | — | — | — | 7.778 ± 21.508 | 18.313 ± 14.697 | 16.500 ± NA |
| week 12 | — | — | — | — | 19.410 ± 21.832 | 24.853 ± 18.181 | 22.320 ± NA |
| week 24 | — | — | — | — | 13.893 ± 14.892 | 25.174 ± 24.052 | — |
| week 36 | — | — | — | — | — | -20.450 ± NA | — |
| week 48 | — | — | — | — | 19.070 ± 16.317 | -6.863 ± 12.464 | — |
| Early termination | 0.650 ± NA | — | — | — | 2.684 ± 30.133 | -11.136 ± 14.539 | 5.533 ± 20.941 |
Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.
| percentage | Part A - MYH7 - MYK-491 | Part A - TTN - MYK-491 | Part A - DCM-Genetic - MYK-491 | Part A - DCM-Non Genetic - MYK-491 | Part B - MYH7 - MYK-491 | Part B - TTN - MYK-491 | Part B - DCM-Non Genetic - MYK-491 |
|---|---|---|---|---|---|---|---|
| End of treatment period 1 | 4.78 ± 7.40 | 4.94 ± 7.08 | -0.75 ± 3.06 | 2.47 ± 6.14 | — | — | — |
| End of treatment period 2 | 8.84 ± 6.43 | 5.94 ± 6.15 | 1.37 ± 5.36 | 4.84 ± 10.00 | — | — | — |
| week 2 | — | — | — | — | 5.53 ± 10.31 | 4.21 ± 11.03 | 5.60 ± 2.12 |
| week 6 | — | — | — | — | 3.31 ± 5.85 | -0.40 ± 7.83 | 14.05 ± 18.03 |
| week 12 | — | — | — | — | 2.44 ± 5.39 | 1.77 ± 5.26 | 7.60 ± NA |
| week 24 | — | — | — | — | -2.78 ± 0.59 | 2.24 ± 8.58 | — |
| week 36 | — | — | — | — | — | 10.80 ± NA | — |
| Week 42 | — | — | — | — | — | 23.60 ± NA | — |
| week 48 | — | — | — | — | 3.85 ± 4.75 | 7.12 ± 11.12 | — |
| Early termination | -3.20 ± NA | — | — | — | -2.94 ± 4.65 | 3.99 ± 9.55 | 4.13 ± 5.87 |
Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.
| percentage | Part A - MYH7 - MYK-491 | Part A - TTN - MYK-491 | Part A - DCM-Genetic - MYK-491 | Part A - DCM-Non Genetic - MYK-491 | Part B - MYH7 - MYK-491 | Part B - TTN - MYK-491 | Part B - DCM-Non Genetic - MYK-491 |
|---|---|---|---|---|---|---|---|
| End of treatment period 1 | -1.41 ± 2.79 | -0.79 ± 2.31 | -0.32 ± 2.81 | -0.36 ± 1.63 | — | — | — |
| End of treatment period 2 | -2.05 ± 2.05 | -1.21 ± 2.23 | -1.92 ± 2.00 | -0.95 ± 2.46 | — | — | — |
| week 2 | — | — | — | — | -1.60 ± 2.59 | -1.84 ± 1.66 | -1.80 ± 2.63 |
| week 6 | — | — | — | — | -2.18 ± 2.53 | -1.90 ± 1.11 | -3.65 ± 0.49 |
| week 12 | — | — | — | — | -2.34 ± 2.03 | -2.00 ± 2.34 | -4.00 ± NA |
| week 24 | — | — | — | — | 0.02 ± 1.25 | -2.62 ± 2.66 | — |
| week 36 | — | — | — | — | — | -2.50 ± NA | — |
| Week 42 | — | — | — | — | — | -7.70 ± NA | — |
| week 48 | — | — | — | — | -2.77 ± 1.99 | -4.33 ± 1.30 | — |
| Early termination | -0.70 ± NA | — | — | — | 0.01 ± 2.12 | -1.31 ± 1.41 | -1.90 ± 1.81 |
Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.
| percentage | Part A - MYH7 - MYK-491 | Part A - TTN - MYK-491 | Part A - DCM-Genetic - MYK-491 | Part A - DCM-Non Genetic - MYK-491 | Part B - MYH7 - MYK-491 | Part B - TTN - MYK-491 | Part B - DCM-Non Genetic - MYK-491 |
|---|---|---|---|---|---|---|---|
| End of treatment period 1 | -3.62 ± 3.73 | 0.58 ± 2.83 | -4.10 ± 4.07 | 0.15 ± 4.47 | — | — | — |
| End of treatment period 2 | -4.00 ± 3.17 | -1.45 ± 3.32 | -2.08 ± 1.25 | -0.78 ± 3.87 | — | — | — |
| week 2 | — | — | — | — | -5.16 ± 4.55 | -3.00 ± 3.64 | -3.25 ± 5.30 |
| week 6 | — | — | — | — | -4.07 ± 3.43 | -4.68 ± 1.11 | -0.10 ± NA |
| week 12 | — | — | — | — | -3.80 ± 1.26 | -0.94 ± 2.65 | 0.00 ± NA |
| week 24 | — | — | — | — | -2.64 ± 4.72 | -0.88 ± 1.94 | — |
| week 36 | — | — | — | — | — | -2.60 ± NA | — |
| Week 42 | — | — | — | — | — | -6.00 ± NA | — |
| week 48 | — | — | — | — | -4.05 ± 3.13 | -3.98 ± 3.43 | — |
| Early termination | 0.40 ± NA | — | — | — | 0.54 ± 5.50 | -1.52 ± 2.38 | 0.40 ± 5.23 |
Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.
| cm/s | Part A - MYH7 - MYK-491 | Part A - TTN - MYK-491 | Part A - DCM-Genetic - MYK-491 | Part A - DCM-Non Genetic - MYK-491 | Part B - MYH7 - MYK-491 | Part B - TTN - MYK-491 | Part B - DCM-Non Genetic - MYK-491 |
|---|---|---|---|---|---|---|---|
| End of treatment period 1 | 0.23 ± 1.90 | -0.12 ± 0.77 | 1.15 ± 0.66 | 0.22 ± 1.62 | — | — | — |
| End of treatment period 2 | 1.01 ± 1.75 | 0.53 ± 1.57 | 1.40 ± 1.38 | -0.10 ± 1.99 | — | — | — |
| week 2 | — | — | — | — | -0.04 ± 1.62 | -0.14 ± 0.88 | -0.95 ± 0.78 |
| week 6 | — | — | — | — | 0.34 ± 0.84 | 0.08 ± 0.59 | -0.80 ± NA |
| week 12 | — | — | — | — | 0.57 ± 1.26 | -0.03 ± 1.29 | — |
| week 24 | — | — | — | — | -0.55 ± 1.33 | 0.18 ± 0.65 | — |
| week 36 | — | — | — | — | — | -0.30 ± NA | — |
| week 48 | — | — | — | — | 1.25 ± 1.35 | 0.10 ± 0.46 | — |
| Early termination | -2.30 ± NA | — | — | — | 0.14 ± 1.43 | 0.67 ± 1.39 | -1.20 ± 0.57 |
Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.
| cm/s | Part A - MYH7 - MYK-491 | Part A - TTN - MYK-491 | Part A - DCM-Genetic - MYK-491 | Part A - DCM-Non Genetic - MYK-491 | Part B - MYH7 - MYK-491 | Part B - TTN - MYK-491 | Part B - DCM-Non Genetic - MYK-491 |
|---|---|---|---|---|---|---|---|
| End of treatment period 1 | 0.56 ± 1.05 | 0.03 ± 0.50 | 0.78 ± 0.63 | 0.06 ± 0.66 | — | — | — |
| End of treatment period 2 | 0.53 ± 0.42 | 0.20 ± 0.62 | 1.04 ± 1.57 | -0.20 ± 0.94 | — | — | — |
| week 2 | — | — | — | — | 0.24 ± 0.90 | 0.06 ± 0.58 | 0.20 ± 1.31 |
| week 6 | — | — | — | — | 0.95 ± 0.89 | 0.50 ± 1.39 | -0.05 ± 1.34 |
| week 12 | — | — | — | — | 0.77 ± 0.83 | -0.12 ± 0.74 | 1.30 ± NA |
| week 24 | — | — | — | — | 0.17 ± 0.53 | 0.17 ± 0.97 | — |
| week 36 | — | — | — | — | — | -1.40 ± NA | — |
| week 48 | — | — | — | — | 1.22 ± 1.27 | 0.07 ± 1.14 | — |
| Early termination | 0.40 ± NA | — | — | — | 0.40 ± 1.53 | 0.10 ± 0.77 | 0.67 ± 1.00 |
Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.
| mm | Part A - MYH7 - MYK-491 | Part A - TTN - MYK-491 | Part A - DCM-Genetic - MYK-491 | Part A - DCM-Non Genetic - MYK-491 | Part B - MYH7 - MYK-491 | Part B - TTN - MYK-491 | Part B - DCM-Non Genetic - MYK-491 |
|---|---|---|---|---|---|---|---|
| End of treatment period 1 | -0.15 ± 4.07 | -2.84 ± 3.47 | 0.10 ± 1.44 | -1.77 ± 5.60 | — | — | — |
| End of treatment period 2 | -3.14 ± 5.97 | -5.48 ± 4.83 | -3.60 ± 3.48 | -2.20 ± 6.03 | — | — | — |
| week 2 | — | — | — | — | -0.90 ± 4.25 | -5.94 ± 3.74 | -4.43 ± 9.40 |
| week 6 | — | — | — | — | -0.17 ± 6.01 | -5.93 ± 4.76 | -2.20 ± NA |
| week 12 | — | — | — | — | -0.92 ± 4.67 | -4.18 ± 4.75 | -1.60 ± NA |
| week 24 | — | — | — | — | -0.07 ± 6.04 | -6.12 ± 4.18 | — |
| week 36 | — | — | — | — | — | -5.80 ± NA | — |
| week 48 | — | — | — | — | 2.90 ± 7.07 | -4.90 ± 3.53 | — |
| Early termination | -1.50 ± NA | — | — | — | 1.33 ± 10.57 | -0.77 ± 3.86 | -0.60 ± 5.36 |
Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.
| mL/m^2 | Part A - MYH7 - MYK-491 | Part A - TTN - MYK-491 | Part A - DCM-Genetic - MYK-491 | Part A - DCM-Non Genetic - MYK-491 | Part B - MYH7 - MYK-491 | Part B - TTN - MYK-491 | Part B - DCM-Non Genetic - MYK-491 |
|---|---|---|---|---|---|---|---|
| End of treatment period 1 | -8.3128 ± 9.2045 | -2.8341 ± 10.6672 | 1.5998 ± 2.6613 | -3.1748 ± 6.3863 | — | — | — |
| End of treatment period 2 | -9.0315 ± 10.6354 | -7.0016 ± 8.8423 | -1.7459 ± 6.9756 | -4.3387 ± 8.9773 | — | — | — |
| week 2 | — | — | — | — | -16.6661 ± 27.1117 | -6.1675 ± 12.9178 | -3.7087 ± 2.2142 |
| week 6 | — | — | — | — | -6.8323 ± 14.6055 | -7.9134 ± 10.2267 | -13.2403 ± 18.8755 |
| week 12 | — | — | — | — | -5.5205 ± 9.5934 | -9.9285 ± 14.1805 | -0.9776 ± NA |
| week 24 | — | — | — | — | -2.2674 ± 14.6852 | -6.6309 ± 19.3049 | — |
| week 36 | — | — | — | — | — | -21.4681 ± 6.5099 | — |
| Week 42 | — | — | — | — | — | -29.9173 ± NA | — |
| week 48 | — | — | — | — | -13.5827 ± 21.5043 | -18.4947 ± 12.9649 | — |
| Early termination | 1.2208 ± NA | — | — | — | -2.3523 ± 14.4189 | -6.7128 ± 15.2440 | 2.9170 ± 6.0452 |
Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.
| mm | Part A - MYH7 - MYK-491 | Part A - TTN - MYK-491 | Part A - DCM-Genetic - MYK-491 | Part A - DCM-Non Genetic - MYK-491 | Part B - MYH7 - MYK-491 | Part B - TTN - MYK-491 | Part B - DCM-Non Genetic - MYK-491 |
|---|---|---|---|---|---|---|---|
| End of treatment period 1 | 0.48 ± 3.61 | -2.49 ± 3.51 | -0.60 ± 3.91 | -1.37 ± 5.14 | — | — | — |
| End of treatment period 2 | -0.85 ± 4.36 | -3.12 ± 3.34 | -3.50 ± 3.84 | -1.77 ± 4.60 | — | — | — |
| week 2 | — | — | — | — | -5.11 ± 9.22 | -3.56 ± 4.03 | -5.00 ± 7.04 |
| week 6 | — | — | — | — | -1.75 ± 3.34 | -3.10 ± 2.61 | 0.30 ± NA |
| week 12 | — | — | — | — | -2.09 ± 3.58 | -0.17 ± 2.64 | 0.90 ± NA |
| week 24 | — | — | — | — | -2.10 ± 2.50 | -2.86 ± 5.87 | — |
| week 36 | — | — | — | — | — | -3.10 ± NA | — |
| Week 42 | — | — | — | — | — | -1.50 ± NA | — |
| week 48 | — | — | — | — | -3.40 ± 3.64 | -2.13 ± 3.40 | — |
| Early termination | 3.60 ± NA | — | — | — | -1.97 ± 5.36 | 0.46 ± 3.40 | 2.70 ± 1.13 |
Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.
| m1/m2 | Part A - MYH7 - MYK-491 | Part A - TTN - MYK-491 | Part A - DCM-Genetic - MYK-491 | Part A - DCM-Non Genetic - MYK-491 | Part B - MYH7 - MYK-491 | Part B - TTN - MYK-491 | Part B - DCM-Non Genetic - MYK-491 |
|---|---|---|---|---|---|---|---|
| End of treatment period 1 | -7.3006 ± 7.0043 | 0.4855 ± 10.8288 | 1.3937 ± 3.9810 | -3.6715 ± 8.4975 | — | — | — |
| End of treatment period 2 | -4.3719 ± 11.6238 | -4.4642 ± 12.9621 | -1.1050 ± 6.1575 | -2.1417 ± 12.8270 | — | — | — |
| week 2 | — | — | — | — | -19.7184 ± 31.0876 | -6.7773 ± 10.3963 | 0.2596 ± 0.0152 |
| week 6 | — | — | — | — | -6.2694 ± 17.5060 | -12.9208 ± 11.0202 | -11.4771 ± 18.4933 |
| week 12 | — | — | — | — | -5.2247 ± 11.4301 | -11.7627 ± 17.1607 | 7.4828 ± NA |
| week 24 | — | — | — | — | -5.9020 ± 20.7779 | -6.2700 ± 24.3104 | — |
| week 36 | — | — | — | — | — | -13.0453 ± 5.3813 | — |
| Week 42 | — | — | — | — | — | -11.8121 ± NA | — |
| week 48 | — | — | — | — | -14.3351 ± 24.7973 | -18.5657 ± 6.0845 | — |
| Early termination | -1.6197 ± NA | — | — | — | -7.2323 ± 24.2148 | -6.7050 ± 17.2581 | 8.3887 ± 3.3592 |
Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.
| cm/s | Part A - MYH7 - MYK-491 | Part A - TTN - MYK-491 | Part A - DCM-Genetic - MYK-491 | Part A - DCM-Non Genetic - MYK-491 | Part B - MYH7 - MYK-491 | Part B - TTN - MYK-491 | Part B - DCM-Non Genetic - MYK-491 |
|---|---|---|---|---|---|---|---|
| End of treatment period 1 | 0.55 ± 1.63 | 0.37 ± 2.51 | 1.23 ± 1.21 | 0.46 ± 3.27 | — | — | — |
| End of treatment period 2 | 0.51 ± 1.50 | 0.58 ± 2.97 | 2.60 ± 3.38 | -0.66 ± 2.23 | — | — | — |
| week 2 | — | — | — | — | 0.23 ± 2.77 | 0.42 ± 1.47 | -1.30 ± 1.51 |
| week 6 | — | — | — | — | 0.43 ± 1.18 | -0.14 ± 1.29 | -1.30 ± 0.99 |
| week 12 | — | — | — | — | 0.83 ± 1.99 | -1.48 ± 2.36 | -3.20 ± NA |
| week 24 | — | — | — | — | 0.15 ± 1.52 | -0.40 ± 2.09 | — |
| week 36 | — | — | — | — | — | -1.80 ± NA | — |
| week 48 | — | — | — | — | 2.25 ± 1.89 | -0.30 ± 1.60 | — |
| Early termination | -0.60 ± NA | — | — | — | 0.20 ± 2.85 | 0.37 ± 2.28 | 2.23 ± 2.16 |
Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.
| cm/s | Part A - MYH7 - MYK-491 | Part A - TTN - MYK-491 | Part A - DCM-Genetic - MYK-491 | Part A - DCM-Non Genetic - MYK-491 | Part B - MYH7 - MYK-491 | Part B - TTN - MYK-491 | Part B - DCM-Non Genetic - MYK-491 |
|---|---|---|---|---|---|---|---|
| End of treatment period 1 | 0.75 ± 1.66 | 0.26 ± 1.62 | -0.05 ± 1.35 | -0.73 ± 1.30 | — | — | — |
| End of treatment period 2 | -0.04 ± 0.86 | 0.28 ± 1.59 | 0.84 ± 1.12 | -0.32 ± 1.32 | — | — | — |
| week 2 | — | — | — | — | 0.51 ± 1.43 | -0.84 ± 1.52 | -0.17 ± 1.12 |
| week 6 | — | — | — | — | 0.58 ± 1.12 | -0.73 ± 1.94 | -0.10 ± 2.97 |
| week 12 | — | — | — | — | 0.60 ± 1.16 | -0.86 ± 1.23 | 1.90 ± NA |
| week 24 | — | — | — | — | -0.65 ± 0.76 | -0.75 ± 0.91 | — |
| week 36 | — | — | — | — | — | -5.10 ± NA | — |
| week 48 | — | — | — | — | 1.75 ± 1.32 | -1.50 ± 1.93 | — |
| Early termination | 0.60 ± NA | — | — | — | 1.04 ± 1.65 | 0.04 ± 1.25 | 1.03 ± 2.58 |
Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.
| E/E prime ratio | Part A - MYH7 - MYK-491 | Part A - TTN - MYK-491 | Part A - DCM-Genetic - MYK-491 | Part A - DCM-Non Genetic - MYK-491 | Part B - MYH7 - MYK-491 | Part B - TTN - MYK-491 | Part B - DCM-Non Genetic - MYK-491 |
|---|---|---|---|---|---|---|---|
| End of treatment period 1 | -2.45 ± 3.16 | 0.07 ± 3.67 | -0.20 ± 4.46 | 0.41 ± 3.23 | — | — | — |
| End of treatment period 2 | -2.15 ± 2.88 | 0.45 ± 2.99 | -2.16 ± 3.92 | 1.03 ± 2.60 | — | — | — |
| week 2 | — | — | — | — | -1.43 ± 4.37 | -0.03 ± 4.40 | -0.03 ± 0.47 |
| week 6 | — | — | — | — | -1.19 ± 4.09 | -0.15 ± 5.41 | 1.25 ± 1.20 |
| week 12 | — | — | — | — | -2.24 ± 1.56 | -0.47 ± 3.85 | 0.60 ± NA |
| week 24 | — | — | — | — | 0.07 ± 4.67 | -0.66 ± 4.24 | — |
| week 36 | — | — | — | — | — | 10.70 ± NA | — |
| week 48 | — | — | — | — | -4.88 ± 2.38 | -1.00 ± 3.89 | — |
| Early termination | -0.90 ± NA | — | — | — | -1.07 ± 3.30 | -0.51 ± 3.91 | -0.03 ± 0.93 |
Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.
| E/E prime ratio | Part A - MYH7 - MYK-491 | Part A - TTN - MYK-491 | Part A - DCM-Genetic - MYK-491 | Part A - DCM-Non Genetic - MYK-491 | Part B - MYH7 - MYK-491 | Part B - TTN - MYK-491 | Part B - DCM-Non Genetic - MYK-491 |
|---|---|---|---|---|---|---|---|
| End of treatment period 1 | -1.29 ± 1.72 | -0.08 ± 3.68 | -1.80 ± 5.60 | -0.49 ± 3.94 | — | — | — |
| End of treatment period 2 | -1.14 ± 2.23 | 0.12 ± 2.94 | -3.58 ± 4.88 | 0.73 ± 3.93 | — | — | — |
| week 2 | — | — | — | — | -1.07 ± 2.88 | -1.00 ± 1.98 | 0.77 ± 1.42 |
| week 6 | — | — | — | — | -0.75 ± 4.23 | -1.34 ± 2.15 | 1.80 ± 2.55 |
| week 12 | — | — | — | — | -2.17 ± 2.45 | 2.48 ± 5.43 | 4.00 ± NA |
| week 24 | — | — | — | — | -0.45 ± 3.99 | -0.47 ± 2.94 | — |
| week 36 | — | — | — | — | — | 5.00 ± NA | — |
| week 48 | — | — | — | — | -4.08 ± 3.06 | -1.47 ± 1.44 | — |
| Early termination | 0.20 ± NA | — | — | — | -0.91 ± 3.39 | 0.75 ± 5.92 | 0.10 ± 0.62 |
Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.
| E/E prime ratio | Part A - MYH7 - MYK-491 | Part A - TTN - MYK-491 | Part A - DCM-Genetic - MYK-491 | Part A - DCM-Non Genetic - MYK-491 | Part B - MYH7 - MYK-491 | Part B - TTN - MYK-491 | Part B - DCM-Non Genetic - MYK-491 |
|---|---|---|---|---|---|---|---|
| End of treatment period 1 | -3.12 ± 4.51 | -0.91 ± 3.78 | 0.65 ± 2.89 | 1.86 ± 2.30 | — | — | — |
| End of treatment period 2 | -1.45 ± 2.14 | 0.07 ± 4.00 | -1.38 ± 2.82 | 1.32 ± 3.07 | — | — | — |
| week 2 | — | — | — | — | -1.77 ± 6.75 | 1.50 ± 9.41 | -0.83 ± 1.57 |
| week 6 | — | — | — | — | -1.27 ± 4.43 | 1.33 ± 10.61 | 0.65 ± 0.07 |
| week 12 | — | — | — | — | -2.27 ± 3.53 | -1.30 ± 3.68 | -2.70 ± NA |
| week 24 | — | — | — | — | 0.70 ± 5.41 | -2.03 ± 7.68 | — |
| week 36 | — | — | — | — | — | 16.50 ± NA | — |
| week 48 | — | — | — | — | -5.68 ± 4.89 | 0.05 ± 7.37 | — |
| Early termination | -2.00 ± NA | — | — | — | -1.19 ± 3.67 | -1.19 ± 4.95 | -0.27 ± 2.20 |
Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.
| E/A ratio | Part A - MYH7 - MYK-491 | Part A - TTN - MYK-491 | Part A - DCM-Genetic - MYK-491 | Part A - DCM-Non Genetic - MYK-491 | Part B - MYH7 - MYK-491 | Part B - TTN - MYK-491 | Part B - DCM-Non Genetic - MYK-491 |
|---|---|---|---|---|---|---|---|
| End of treatment period 1 | 0.02 ± 0.16 | -0.01 ± 0.32 | -0.10 ± 0.10 | 0.04 ± 0.11 | — | — | — |
| End of treatment period 2 | -0.16 ± 0.40 | -0.08 ± 0.37 | -0.26 ± 0.54 | -0.04 ± 0.15 | — | — | — |
| week 2 | — | — | — | — | 0.07 ± 0.92 | -0.32 ± 0.40 | -0.12 ± 0.21 |
| week 6 | — | — | — | — | -0.25 ± 0.45 | -0.58 ± 0.77 | 0.15 ± 0.21 |
| week 12 | — | — | — | — | -0.23 ± 0.50 | -0.76 ± 0.70 | 0.20 ± NA |
| week 24 | — | — | — | — | 0.00 ± 0.10 | -0.53 ± 0.78 | — |
| week 36 | — | — | — | — | — | 0.20 ± NA | — |
| week 48 | — | — | — | — | -0.40 ± 0.52 | -0.77 ± 0.85 | — |
| Early termination | 0.70 ± NA | — | — | — | -0.10 ± 0.32 | -0.37 ± 0.52 | 0.17 ± 0.06 |
Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.
| mL | Part A - MYH7 - MYK-491 | Part A - TTN - MYK-491 | Part A - DCM-Genetic - MYK-491 | Part A - DCM-Non Genetic - MYK-491 | Part B - MYH7 - MYK-491 | Part B - TTN - MYK-491 | Part B - DCM-Non Genetic - MYK-491 |
|---|---|---|---|---|---|---|---|
| End of treatment period 1 | -2.545 ± 4.182 | -0.374 ± 8.947 | -3.663 ± 9.552 | -0.563 ± 3.670 | — | — | — |
| End of treatment period 2 | -3.985 ± 5.681 | 0.049 ± 8.529 | -3.993 ± 5.672 | -2.866 ± 6.613 | — | — | — |
| week 2 | — | — | — | — | 0.509 ± 11.279 | -3.807 ± 9.917 | 2.817 ± 8.224 |
| week 6 | — | — | — | — | 3.430 ± 9.313 | -10.938 ± 22.821 | 1.680 ± 5.374 |
| week 12 | — | — | — | — | -3.409 ± 13.577 | -13.953 ± 24.798 | 9.950 ± NA |
| week 24 | — | — | — | — | -2.858 ± 16.826 | -5.214 ± 32.177 | — |
| week 36 | — | — | — | — | — | -16.410 ± NA | — |
| Week 42 | — | — | — | — | — | -27.640 ± NA | — |
| week 48 | — | — | — | — | -7.560 ± 7.287 | -19.843 ± 24.404 | — |
| Early termination | 12.030 ± NA | — | — | — | 1.313 ± 13.248 | -4.793 ± 19.027 | 10.607 ± 3.279 |
Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.
| mL/m^2 | Part A - MYH7 - MYK-491 | Part A - TTN - MYK-491 | Part A - DCM-Genetic - MYK-491 | Part A - DCM-Non Genetic - MYK-491 | Part B - MYH7 - MYK-491 | Part B - TTN - MYK-491 | Part B - DCM-Non Genetic - MYK-491 |
|---|---|---|---|---|---|---|---|
| End of treatment period 1 | -0.6427 ± 5.0007 | 0.9860 ± 7.1462 | -0.6320 ± 9.1208 | -0.0084 ± 2.4459 | — | — | — |
| End of treatment period 2 | -0.3419 ± 4.2365 | 1.1617 ± 6.0815 | -1.1870 ± 7.2047 | -0.2139 ± 2.5533 | — | — | — |
| week 2 | — | — | — | — | 0.1346 ± 6.4456 | -0.1818 ± 5.1802 | 2.3315 ± 9.2253 |
| week 6 | — | — | — | — | 1.1887 ± 4.2647 | -5.5545 ± 13.4164 | -0.5969 ± 10.1570 |
| week 12 | — | — | — | — | -1.9834 ± 9.0618 | -7.1717 ± 14.8684 | 7.8293 ± NA |
| week 24 | — | — | — | — | -2.3145 ± 11.3192 | -1.8423 ± 17.8500 | — |
| week 36 | — | — | — | — | — | -13.3385 ± 3.1173 | — |
| Week 42 | — | — | — | — | — | -11.7208 ± NA | — |
| week 48 | — | — | — | — | -2.4524 ± 3.4679 | -11.2887 ± 15.6892 | — |
| Early termination | 8.1892 ± NA | — | — | — | -0.0097 ± 6.8537 | -1.4975 ± 9.7454 | 6.5957 ± 3.9106 |
Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days.
| Percent change | Part A - MYH7 - MYK-491 | Part A - TTN - MYK-491 | Part A - DCM-Genetic - MYK-491 | Part A - DCM-Non Genetic - MYK-491 | Part B - MYH7 - MYK-491 | Part B - TTN - MYK-491 | Part B - DCM-Non Genetic - MYK-491 |
|---|---|---|---|---|---|---|---|
| End of treatment period 1 | 5.617 ± 13.459 | 4.675 ± 12.173 | 2.687 ± 26.913 | 2.489 ± 10.953 | — | — | — |
| End of treatment period 2 | 15.504 ± 18.234 | 9.870 ± 15.019 | 8.102 ± 21.513 | 9.655 ± 14.789 | — | — | — |
| week 2 | — | — | — | — | -1.903 ± 19.042 | 15.609 ± 10.759 | 1.058 ± 6.753 |
| week 6 | — | — | — | — | -9.410 ± 20.950 | 21.196 ± 24.108 | -7.265 ± 24.267 |
| week 12 | — | — | — | — | 5.089 ± 17.898 | 24.306 ± 30.693 | -6.694 ± NA |
| week 24 | — | — | — | — | 6.522 ± 23.635 | 19.181 ± 31.252 | — |
| week 36 | — | — | — | — | — | 2.595 ± NA | — |
| Week 42 | — | — | — | — | — | 43.996 ± NA | — |
| week 48 | — | — | — | — | 23.815 ± 26.494 | 27.568 ± 24.279 | — |
| Early termination | -7.060 ± NA | — | — | — | -0.711 ± 30.276 | 11.267 ± 25.412 | -6.924 ± 11.148 |
Baseline is defined as the last non-missing result prior to the first dose of study medication. for part B, baseline is defined as visit 1B regardless of rescreening. Treatment periods 1 and 2 are 5 to 8 days. Higher LAFI values are considered better left atrial function while lower LFAI values may indicate left atrial dysfunction.
| Index | Part A - MYH7 - MYK-491 | Part A - TTN - MYK-491 | Part A - DCM-Genetic - MYK-491 | Part A - DCM-Non Genetic - MYK-491 | Part B - MYH7 - MYK-491 | Part B - TTN - MYK-491 | Part B - DCM-Non Genetic - MYK-491 |
|---|---|---|---|---|---|---|---|
| End of treatment period 1 | 5.2299 ± 5.3847 | 1.6645 ± 11.9891 | -0.4600 ± 1.6721 | 0.3524 ± 5.0864 | — | — | — |
| End of treatment period 2 | 11.1434 ± 10.5287 | 6.8482 ± 13.2805 | 1.6243 ± 5.5803 | 3.6366 ± 6.4861 | — | — | — |
| week 2 | — | — | — | — | 4.1989 ± 10.0937 | 5.6654 ± 7.6211 | -10.2619 ± 21.2810 |
| week 6 | — | — | — | — | 0.7215 ± 23.0068 | 9.9039 ± 8.9999 | 1.3624 ± 15.4676 |
| week 12 | — | — | — | — | 5.3578 ± 14.5382 | 8.4149 ± 7.3469 | -22.1266 ± NA |
| week 24 | — | — | — | — | -4.8648 ± 19.3724 | 8.1890 ± 8.8584 | — |
| week 36 | — | — | — | — | — | 8.6083 ± 8.6083 | — |
| week 48 | — | — | — | — | 6.3041 ± 18.4543 | 12.8222 ± 14.0703 | — |
| Early termination | -11.0849 ± NA | — | — | — | 0.3925 ± 23.9350 | 2.4252 ± 10.4948 | -20.4736 ± 4.7293 |
Collected over All-cause mortality, serious adverse events, and other adverse events are from first dose until the end of the study visit for the participant (Up to approximately 115 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A - MYH7 - MYK-491 25 mg BID | 0/12 (0%) | 0/12 (0%) | 5/12 (41.7%) |
| Part A - TTN - MYK-491 25 mg BID | 0/14 (0%) | 0/14 (0%) | 3/14 (21.4%) |
| Part A - DCM-Genetic - MYK-491 25 mg BID | 0/5 (0%) | 0/5 (0%) | 1/5 (20%) |
| Part A - DCM-Non Genetic - MYK-491 25 mg BID | 0/10 (0%) | 0/10 (0%) | 2/10 (20%) |
| Part A - MYH7 - MYK-491 50 mg BID | 0/12 (0%) | 0/12 (0%) | 5/12 (41.7%) |
| Part A - TTN - MYK-491 50 mg BID | 0/14 (0%) | 0/14 (0%) | 5/14 (35.7%) |
| Part A - DCM-Genetic - MYK-491 50 mg BID | 0/4 (0%) | 0/4 (0%) | 2/4 (50%) |
| Part A - DCM-Non Genetic - MYK-491 50 mg BID | 0/9 (0%) | 0/9 (0%) | 2/9 (22.2%) |
| Part A - DCM-Genetic - MYK-491 10 mg BID | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
| Part A - DCM-Non Genetic - MYK-491 10 mg BID | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
| Part B - MYH7 - MYK-491 25 mg BID | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Part B - MYH7 - MYK-491 50 mg BID | 0/4 (0%) | 1/4 (25%) | 3/4 (75%) |
| Part B - TTN - MYK-491 50 mg BID | 0/4 (0%) | 1/4 (25%) | 3/4 (75%) |
| Part B - DCM-Non Genetic - MYK-491 50 mg BID | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
| Part B - MYH7 - MYK-491 75 mg BID | 0/5 (0%) | 0/5 (0%) | 5/5 (100%) |
| Part B - TTN - MYK-491 75 mg BID | 0/4 (0%) | 2/4 (50%) | 4/4 (100%) |
| Part B - DCM-Non Genetic - MYK-491 75 mg BID | 0/3 (0%) | 1/3 (33.3%) | 2/3 (66.7%) |
| Event | Part A - MYH7 - MYK-491 25 mg BID | Part A - TTN - MYK-491 25 mg BID | Part A - DCM-Genetic - MYK-491 25 mg BID | Part A - DCM-Non Genetic - MYK-491 25 mg BID | Part A - MYH7 - MYK-491 50 mg BID | Part A - TTN - MYK-491 50 mg BID | Part A - DCM-Genetic - MYK-491 50 mg BID | Part A - DCM-Non Genetic - MYK-491 50 mg BID | Part A - DCM-Genetic - MYK-491 10 mg BID | Part A - DCM-Non Genetic - MYK-491 10 mg BID | Part B - MYH7 - MYK-491 25 mg BID | Part B - MYH7 - MYK-491 50 mg BID | Part B - TTN - MYK-491 50 mg BID | Part B - DCM-Non Genetic - MYK-491 50 mg BID | Part B - MYH7 - MYK-491 75 mg BID | Part B - TTN - MYK-491 75 mg BID | Part B - DCM-Non Genetic - MYK-491 75 mg BID |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cardiac failure congestiveCardiac disorders | 0/12 | 0/14 | 0/5 | 0/10 | 0/12 | 0/14 | 0/4 | 0/9 | 0/1 | 0/1 | 0/1 | 0/4 | 0/4 | 0/1 | 0/5 | 0/4 | 1/3 |
| Arrhythmic stormCardiac disorders | 0/12 | 0/14 | 0/5 | 0/10 | 0/12 | 0/14 | 0/4 | 0/9 | 0/1 | 0/1 | 0/1 | 0/4 | 0/4 | 0/1 | 0/5 | 1/4 | 0/3 |
| Ventricular fibrillationCardiac disorders | 0/12 | 0/14 | 0/5 | 0/10 | 0/12 | 0/14 | 0/4 | 0/9 | 0/1 | 0/1 | 0/1 | 0/4 | 0/4 | 0/1 | 0/5 | 1/4 | 0/3 |
| Liver injuryHepatobiliary disorders | 0/12 | 0/14 | 0/5 | 0/10 | 0/12 | 0/14 | 0/4 | 0/9 | 0/1 | 0/1 | 0/1 | 0/4 | 0/4 | 0/1 | 0/5 | 1/4 | 0/3 |
| Urinary tract infectionInfections and infestations | 0/12 | 0/14 | 0/5 | 0/10 | 0/12 | 0/14 | 0/4 | 0/9 | 0/1 | 0/1 | 0/1 | 1/4 | 0/4 | 0/1 | 0/5 | 0/4 | 0/3 |
| Transient ischaemic attackNervous system disorders | 0/12 | 0/14 | 0/5 | 0/10 | 0/12 | 0/14 | 0/4 | 0/9 | 0/1 | 0/1 | 0/1 | 0/4 | 1/4 | 0/1 | 0/5 | 0/4 | 0/3 |
| Acute kidney injuryRenal and urinary disorders | 0/12 | 0/14 | 0/5 | 0/10 | 0/12 | 0/14 | 0/4 | 0/9 | 0/1 | 0/1 | 0/1 | 0/4 | 0/4 | 0/1 | 0/5 | 1/4 | 0/3 |
| Event | Part A - MYH7 - MYK-491 25 mg BID | Part A - TTN - MYK-491 25 mg BID | Part A - DCM-Genetic - MYK-491 25 mg BID | Part A - DCM-Non Genetic - MYK-491 25 mg BID | Part A - MYH7 - MYK-491 50 mg BID | Part A - TTN - MYK-491 50 mg BID | Part A - DCM-Genetic - MYK-491 50 mg BID | Part A - DCM-Non Genetic - MYK-491 50 mg BID | Part A - DCM-Genetic - MYK-491 10 mg BID | Part A - DCM-Non Genetic - MYK-491 10 mg BID | Part B - MYH7 - MYK-491 25 mg BID | Part B - MYH7 - MYK-491 50 mg BID | Part B - TTN - MYK-491 50 mg BID | Part B - DCM-Non Genetic - MYK-491 50 mg BID | Part B - MYH7 - MYK-491 75 mg BID | Part B - TTN - MYK-491 75 mg BID | Part B - DCM-Non Genetic - MYK-491 75 mg BID |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 0/12 | 0/14 | 0/5 | 0/10 | 1/12 | 0/14 | 0/4 | 0/9 | 0/1 | 0/1 | 1/1 | 0/4 | 1/4 | 0/1 | 1/5 | 1/4 | 0/3 |
| COVID-19Infections and infestations | 0/12 | 0/14 | 0/5 | 0/10 | 1/12 | 0/14 | 0/4 | 0/9 | 0/1 | 0/1 | 0/1 | 0/4 | 2/4 | 0/1 | 0/5 | 1/4 | 1/3 |
| Respiratory tract infectionInfections and infestations | 0/12 | 0/14 | 0/5 | 0/10 | 0/12 | 0/14 | 0/4 | 0/9 | 0/1 | 0/1 | 0/1 | 1/4 | 2/4 | 0/1 | 1/5 | 0/4 | 0/3 |
| HypotensionVascular disorders | 0/12 | 0/14 | 0/5 | 0/10 | 0/12 | 0/14 | 0/4 | 0/9 | 0/1 | 0/1 | 0/1 | 1/4 | 0/4 | 0/1 | 0/5 | 2/4 | 1/3 |
| FatigueGeneral disorders | 2/12 | 0/14 | 0/5 | 0/10 | 1/12 | 0/14 | 0/4 | 0/9 | 0/1 | 0/1 | 0/1 | 0/4 | 0/4 | 0/1 | 1/5 | 1/4 | 1/3 |
| Atrial flutterCardiac disorders | 0/12 | 0/14 | 0/5 | 0/10 | 0/12 | 0/14 | 0/4 | 0/9 | 0/1 | 0/1 | 0/1 | 1/4 | 0/4 | 0/1 | 0/5 | 0/4 | 0/3 |
| Cardiac failureCardiac disorders | 0/12 | 0/14 | 0/5 | 0/10 | 0/12 | 0/14 | 0/4 | 0/9 | 0/1 | 0/1 | 0/1 | 0/4 | 1/4 | 0/1 | 0/5 | 1/4 | 0/3 |
| PalpitationsCardiac disorders | 1/12 | 0/14 | 0/5 | 0/10 | 0/12 | 0/14 | 0/4 | 0/9 | 0/1 | 0/1 | 0/1 | 1/4 | 0/4 | 0/1 | 0/5 | 0/4 | 0/3 |
| Ventricular extrasystolesCardiac disorders | 0/12 | 0/14 | 0/5 | 0/10 | 0/12 | 0/14 | 0/4 | 0/9 | 0/1 | 0/1 | 0/1 | 0/4 | 0/4 | 0/1 | 0/5 | 1/4 | 0/3 |
| Ventricular tachycardiaCardiac disorders | 0/12 | 0/14 | 0/5 | 0/10 | 0/12 | 0/14 | 0/4 | 0/9 | 0/1 | 0/1 | 0/1 | 0/4 | 0/4 | 0/1 | 0/5 | 1/4 | 0/3 |
| Age, Categorical(Participants) | Part A - MYH7 - MYK-491 | Part A - TTN - MYK-491 | Part A - DCM-Genetic - MYK-491 | Part A - DCM-Non Genetic - MYK-491 | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 11 | 12 | 4 | 9 | 36 |
| >=65 years | 1 | 2 | 1 | 1 | 5 |
| Sex: Female, Male(Participants) | Part A - MYH7 - MYK-491 | Part A - TTN - MYK-491 | Part A - DCM-Genetic - MYK-491 | Part A - DCM-Non Genetic - MYK-491 | Total |
|---|---|---|---|---|---|
| Female | 7 | 4 | 2 | 2 | 15 |
| Male | 5 | 10 | 3 | 8 | 26 |
| Ethnicity (NIH/OMB)(Participants) | Part A - MYH7 - MYK-491 | Part A - TTN - MYK-491 | Part A - DCM-Genetic - MYK-491 | Part A - DCM-Non Genetic - MYK-491 | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 3 | 1 | 1 | 0 | 5 |
| Not Hispanic or Latino | 9 | 13 | 3 | 10 | 35 |
| Unknown or Not Reported | 0 | 0 | 1 | 0 | 1 |
| Race/Ethnicity, Customized(Participants) | Part A - MYH7 - MYK-491 | Part A - TTN - MYK-491 | Part A - DCM-Genetic - MYK-491 | Part A - DCM-Non Genetic - MYK-491 | Total |
|---|---|---|---|---|---|
| Asian | 1 | 0 | 0 | 0 | 1 |
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 2 | 2 |
| Native Hawaiian or other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| White | 11 | 14 | 5 | 8 | 38 |
| Uknown | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2020 to primary completion in Feb 2024, 42 months.
Results were first posted in May 2025, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Danicamtiv